DAVID WARNOCK, MD
Director of the Division of Nephrology
Professor of Medicine and Physiology
University of Alabama at Birmingham
Birmingham, AL USA
David G. Warnock, MD is the Director of the Division of Nephrology and
Professor of Medicine and Physiology at the University of Alabama at Birmingham.
He graduated from the University of California at Berkeley and received
his MD degree from the University of California, San Francisco. His clinical
training was completed at the University of California, San Francisco,
including a 1 year research fellowship with Isidore Edelman, MD in the
Cardiovascular Research Institute.
Following a fellowship with Maurice Burg, MD at the NIH, Dr. Warnock returned
to UCSF as a faculty member. He served as the Section Chief at the San
Francisco VA Medical Center during the last 5 years of his appointment
at UCSF. Following a sabbatical with Bernard Rossier, MD at the Institute
of Pharmacology in Lausanne, Switzerland, Dr. Warnock was recruited to
UAB as the Director of Nephrology in 1988. Since May 1, 2005, Dr. Warnock
has also served at the Director of the Office of Human Research at UAB.
Dr. Warnock's research interests include acid-base physiology,
sodium transport mechanisms, chronic kidney disease, and inherited renal
diseases. He is a member of the American Society for Clinical Investigation,
American Association of Physicians, American Physiologic Society, ASN,
NFK and ISN. He is currently serving as the President of the National
Society of Clinical Investigation
Association of Physicians
Kidney Foundation President
Renal REGARDS, Fabry Registry, Inherited Disease of Electrolyte Transport
My focus is on the factors, genetic and environmental that contribute
to hypertension and chronic kidney disease. The spectrum extends from
basic studies of salt and water transport systems to population based
studies of the prevalence of CKD and the association with stroke and heart
disease. We currently have an approved ancillary study of the REGARDS
project; a prospective cohort evaluation of 30,000 participants 5 yrs
of age to examine the effects of anemia and chronic kidney disease on
the incidence of stroke and heart disease. Another are focuses on inherited
disorders of renal function, with a current emphasis on the renal manifestations
of Fabry disease. Over 40 patients with Fabry disease have been identified
in Alabama and 20 of them have been started on Enzyme Replacement Therapy.
K, Regidor DL, McAllister CJ, Michael B, Warnock DG.
Time-Dependent Associations between Indices of Iron Store and Mortality
in Hemodialysis Patients.
J Am Soc Nephrol. 2005 Jul
DG. Fabry disease: diagnosis and management, with emphasis on the renal
Curr Opin Nephrol Hypertens. 2005 Mar;14(2):87-95.
P, Loffing J, Warnock DG. Sodium and potassium handling by the aldosterone-sensitive
distal nephron: the pivotal role of the distal and connecting tubule.
Am J Physiol Renal Physiol. 2004 Oct;287(4):F593-601.
DG. Renal genetic disorders related to K+ and Mg2+.
Annu Rev Physiol. 2002;64:845-76.